420 with CNW — Medical Cannabis Firm Sues DEA Over Unjustifiable Licensing Delays
A medical marijuana company that focuses on developing cannabis-derived pharmaceuticals has filed a suit against the U.S. Drug Enforcement Administration (DEA) over “exponential delays” in the agency’s licensing process for cultivating medical research cannabis. MMJ BioPharma Cultivation sued the DEA in the U.S. Court of Appeals for the DC Circuit, claiming that the DEA’s licensing process, which can take several years, has prevented innovation which could help patients and which hamper the company’s business. The Rhode Island-based medical cannabis company asked the federal court to compel the DEA into action and hopefully streamline its licensing process. MMJ said in its…

















